481M-9

PAX-7 (MRQ-69) Mouse Monoclonal Antibody

Properties

• biological source: mouse
• Quality Level: 100; 500
• conjugate: unconjugated
• antibody form: culture supernatant
• antibody product type: primary antibodies
• clone: MRQ-69, monoclonal
• description: For In Vitro Diagnostic Use in Select Regions
• form: buffered aqueous solution
• species reactivity: human
• packaging: vial of 0.1 mL concentrate (481M-94); vial of 0.1 mL concentrate Research Use Only (481M-94-RUO); vial of 0.5 mL concentrate (481M-95); vial of 1.0 mL concentrate (481M-96); vial of 1.0 mL concentrate Research Use Only (481M-96-RUO); vial of 1.0 mL pre-dilute Research Use Only (481M-97-RUO); vial of 1.0 mL pre-dilute ready-to-use (481M-97); vial of 7.0 mL pre-dilute ready-to-use (481M-98); vial of 7.0 mL pre-dilute ready-to-use Research Use Only (481M-98-RUO)
• manufacturer/tradename: Cell Marque^™
• technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:200 (concentrated)
• isotype: IgG
• control: Ewing’s sarcoma, rhabdomyosarcoma
• shipped in: wet ice
• storage temp.: 2-8°C
• visualization: nuclear

Description

General description

The paired-box (PAX) family of proteins are key transcriptional regulators involved in early critical development.¹ The PAX-7 transcription factor has important functions in mammalian myogenesis and early neural development, with a particularly crucial role in specification and self-renewal of skeletal muscle tissue.^2,3 The expression of PAX-7 is highly restricted in normal adult tissues as demonstrated by nuclear immunoreactivity only being identified in rare, scattered satellite cells of the skeletal muscle and absent in both visceral smooth muscle and cardiac muscle as well as in a broad anatomical range of other non-neoplastic tissues. The assessment of soft tissue tumors and small round cell tumors is a persistent diagnostic challenge because of overlapping morphological features and insufficient molecular characterization in these groups of neoplasms. A high frequency of strong PAX-7 nuclear expression has been identified predominantly in rhabdomyosarcomas, preferentially in the embryonal subtype, and Ewing′s sarcoma, with reactivity being absent in related malignancies such as leiomyosarcoma, lymphoblastic lymphoma, neuroblastoma, carcinoid tumor, gastrointestinal stromal tumor, and small cell lung carcinoma. Immunohistochemical detection of PAX-7 protein can be used as a tool in distinguishing embryonal rhabdomyosarcoma and Ewing′s sarcoma from histologic mimics.^4,5

Quality

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany